Showing 1 - 3 results of 3 for search 'Inge LeFevre', query time: 0.02s Refine Results
  1. 1
    An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

    An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a... by Sanjay S. Patel, Peter Winkle, Alice Faccin, Francesco Nordio, Inge LeFevre, Claudia Galindo Tsoukas

    Published 2023-08-01
    Get full text
    Article
  2. 2
    Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

    Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults by Inge LeFevre, Lulu Bravo, Nicolas Folschweiller, Eduardo Lopez Medina, Edson Duarte Moreira, Francesco Nordio, Mayuri Sharma, Leslie M. Tharenos, Vianney Tricou, Veerachai Watanaveeradej, Peter J. Winkle, Shibadas Biswal

    Published 2023-05-01
    Get full text
    Article
  3. 3
    Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City

    Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City by Shibadas Biswal, Jorge Fernando Mendez Galvan, Mercedes Macias Parra, Juan-Francisco Galan-Herrera, Monica Belisa Carrascal Rodriguez, Esteban Patricio Rodriguez Bueno, Manja Brose, Martina Rauscher, Inge LeFevre, Derek Wallace, Astrid Borkowski

    Published 2021-06-01
    Get full text
    Article

Search Tools: